Infinity Bio, Inc., a biotech startup pioneering immune system analytics, has raised $8 million in Series A funding to scale its AI platform that reads antibody signals and decodes real-time immune system activity. The round was led by Illumina Ventures and PTX Capital, with participation from Blackbird BioVentures and the Propel Baltimore Fund.

Founded by Joy M. Nassif, Infinity Bio is unlocking a new layer of immune intelligence that could transform the way we diagnose, treat, and monitor disease. By analyzing antibody repertoires using advanced pattern recognition and machine learning, the company is turning raw immune signals into actionable insights for biotech, pharma, and clinical medicine.

In a world where immunology is central to precision health, Infinity Bio aims to make the immune system not just observable - but readable.

---

What Infinity Bio Does

Infinity Bio has built a proprietary platform that deciphers complex immune responses by analyzing antibodies - the molecules the body produces in response to infection, autoimmunity, vaccines, and cancer.

Key features include:

• High-resolution antibody signal processing, using custom assays and ML-powered data interpretation
  
• Cross-sectional and longitudinal immune profiling to track changes over time or across populations
  
• Disease-state modeling to correlate immune signatures with health outcomes
  
• API access and lab integration for biopharma, CROs, and academic partners
  

Think of Infinity Bio as the immune system’s translator. It takes the language of antibodies - normally vast, unstructured, and biologically noisy - and turns it into clean, usable data that reveals what the immune system has seen, how it’s responding, and what it might do next.

This has implications across immuno-oncology, infectious disease, autoimmune conditions, and even neurodegeneration - any area where the immune system plays a role but is hard to measure in real time.

---

Why It Matters

The immune system is incredibly powerful - but frustratingly opaque. Most diagnostic tools today only sample fragments of immune activity, often missing broader trends or contextual meaning.

Infinity Bio is building a system-wide lens: one that captures the full complexity of immune signaling and applies AI to extract meaning from it.

This capability could:

• Enable early disease detection, before symptoms arise
  
• Stratify patients for clinical trials, improving trial success rates
  
• Reveal how therapies modulate the immune system, enabling better drug targeting
  
• Support personalized treatment decisions, based on real-time immune data
  

Here’s something most founders in healthtech miss: if your data product doesn’t already map to a line item on a clinical or R&D budget, it’s not a product  -  it’s a feature in search of a workflow. What Infinity Bio has done well is not just capture biological complexity, but slot their output directly into the daily decisions that matter for drug developers, trial designers, and translational scientists. They aren’t asking the market to adopt a new decision-making paradigm  -  they’re inserting intelligence into the one that already exists.

That’s a huge unlock. Because building a technically brilliant bio-AI stack is table stakes now. The advantage lies in productizing signal in ways that match the rhythm of institutional decisions  -  not just their ambition. Founders often think of "platform" as a badge of scale. But in biotech, platform means "instrumental to someone else's risk." That’s where Infinity Bio is positioning itself: as the immune co-pilot inside someone else's mission-critical workflow.

---

The Market Opportunity: Immune Intelligence as a Platform

As biotech pivots toward systems-level biology, the demand for immune intelligence is skyrocketing.

• The global immunology diagnostics market is projected to reach $27.2 billion by 2030, driven by infectious disease surveillance, chronic care, and oncology (Precedence Research)
  
• Antibody discovery technologies are forecasted to hit $6.3 billion by 2028 (MarketsandMarkets)
  
• The AI in healthcare market is growing at 37% CAGR, with applications in bioinformatics and immune modeling leading adoption (Statista)
  
• By 2026, 70% of healthcare providers are expected to integrate real-time biomarker data into clinical decisions (Gartner)
  

And yet, while sequencing, imaging, and digital pathology have advanced rapidly, immune interpretation tools remain rudimentary. Infinity Bio is filling that gap - making antibodies as data-rich and useful as genomes.

Its platform doesn't compete with ELISA or flow cytometry - it complements and contextualizes them. That’s why it’s drawing attention not just from VCs, but from pharma labs and translational researchers hungry for next-gen immune metrics.

---

What’s Next for Infinity Bio?

With its new $8 million funding, Infinity Bio will focus on scaling its platform and accelerating R&D partnerships.

Roadmap highlights include:

• Expansion of antibody datasets across disease categories and demographics
  
• Partnerships with biotech and academic labs working in oncology, infectious disease, and autoimmune disorders
  
• Integration into drug discovery workflows, offering immune fingerprints to inform pipeline decisions
  
• Deployment of developer tools and APIs, enabling immune intelligence to plug into broader bioinformatics stacks
  
• Hiring across immunology, data science, software engineering, and translational research
  

Infinity Bio’s long-term vision is bold: to become the immune interpretation layer for modern medicine. In a landscape where immune function determines everything from therapy response to vaccine efficacy, being able to “read antibodies” isn’t a nice-to-have - it’s a necessity.

And Infinity Bio is turning that vision into infrastructure.